Table I.
Patient characteristics.
| Groups | ||||
|---|---|---|---|---|
| Characteristics | <65 years n=80, n (%) | ≥65 years n=34, n (%) | P-value | |
| Age, years | Median (Q1, Q3) | 51 (47, 58) | 71 (68,73) | <0.001 |
| BMI, kg/m2 | Median (Q1, Q3) | 22.7 (19.9, 24.9) | 22.2 (20.2, 24.2) | 0.57 |
| PS | 0 | 61 (76.2) | 26 (76.5) | 0.63 |
| 1 | 17 (21.2) | 6 (17.6) | ||
| 2 | 2 (2.5) | 2 (5.9) | ||
| Histological type | Serous | 16 (20.0) | 15 (44.1) | 0.006 |
| Mucinous | 15 (18.8) | 5 (14.7) | ||
| Clear cell | 27 (33.8) | 2 (5.9) | ||
| Endometrioid | 17 (21.2) | 7 (20.6) | ||
| Other | 5 (6.2) | 5 (14.7) | ||
| Stage | I | 31 (38.8) | 5 (14.7) | 0.08 |
| II | 7 (8.8) | 5 (14.7) | ||
| III | 35 (43.8) | 19 (55.9) | ||
| IV | 7 (8.8) | 5 (14.7) | ||
| Nodal status | pN0 | 42 (52.5) | 14 (41.2) | 0.12 |
| pN1 | 18 (22.5) | 5 (14.7) | ||
| pNx | 20 (25.0) | 15 (44.1) | ||
| Albumin, g/dl | Median (Q1, Q3) | 3.9 (3.5, 4.2) | 3.9 (3.3, 4.1) | 0.71 |
| Hemoglobin, g/dl | Median (Q1, Q3) | 12.0 (10.6, 13.1) | 11.9 (11.0, 12.9) | 0.78 |
| CA-125, U/ml | Median (Q1, Q3) | 328.5 (76.5, 1,780.5) | 589.0 (99.5, 3,178.3) | 0.27 |
| NAC | No | 75 (93.8) | 28 (82.4) | 0.12 |
| Yes | 5 (6.2) | 6 (17.6) | ||
| Surgery | No | 1 (1.2) | 1 (2.9) | 1 |
| Yes | 79 (98.8) | 33 (97.1) | ||
| Intraoperative blood loss, ml | Median (Q1, Q3) | 985 (560, 2,160) | 1,060 (515, 1,920) | 0.63 |
| Operative time, min | Median (Q1, Q3) | 246 (195, 299) | 204 (169, 247) | 0.06 |
| Residual tumor | No | 45 (56.2) | 11 (32.4) | 0.03 |
| Yes | 35 (43.8) | 23 (67.6) | ||
| SPTa | No | 34 (42.5) | 17 (50.0) | 0.60 |
| Yes | 46 (57.5) | 17 (50.0) | ||
| Recurrence status | No | 41 (51.2) | 13 (38.2) | 0.29 |
| Yes | 39 (48.8) | 21 (61.8) | ||
| SDS | No | 75 (93.8) | 33 (97.1) | 0.79 |
| Yes | 5 (6.2) | 1 (2.9) | ||
a
SPT was defined as completing at least 6 cycles of adjuvant chemotherapy after surgery in principle. Bold print indicates statistically significant P-values. Q, quartile; BMI, body-mass index; NAC, neoadjuvant chemotherapy; SPT, standard primary therapy; SDS, secondary debulking surgery.